Literature DB >> 24390157

Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration.

Vladimir Miletić1, David Ozretić, Maja Relja.   

Abstract

The term "acquired hepatocerebral degeneration" (AHD) was coined to describe clinical entity distinct from genetically defined Wilson's disease. AHD is chronic neurological disorder, characterized by extrapyramidal and neuropsychiatric symptoms accompanied with advanced liver disease with portosystemic shunts. In majority of AHD cases, extrapyramidal symptoms appear in the presence of known liver disease. Here we present a patient with subacute onset of bilateral, asymmetric, hypokinetic-rigid syndrome and ataxia as initial presentation of liver cirrhosis. Manganese toxicity have major role in AHD pathogenesis. Failure of liver detoxification and presence of portosystemic shunting enables neurotoxic substance of manganese to avoid hepatic metabolism and to enter and accumulate in central nervous system. Predilection brain regions for manganese deposits are globus pallidum (GP) and substantia nigra (SN). Characteristic MRI findings of bilateral, symmetrical hyperintensities of GP and SN on T1-weighted sequences supported the diagnosis of AHD in our patient. In addition, increased T2 signal in dendate nuclei seen in our patient is rare radiological finding. So far, no consensus guidelines regarding medical treatment of AHD exist. We initiated low-dose levodopa treatment, but failed to provide beneficial effect. In conclusion, AHD is distinct clinical entity that should be included in differential diagnosis of both typical and atypical parkinsonian syndromes. Furthermore, our case highlights the importance of performing MRI in patients with atypical parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390157     DOI: 10.1007/s11011-013-9478-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  14 in total

1.  Acquired hepatocerebral degeneration: full recovery after liver transplantation.

Authors:  A Stracciari; M Guarino; P Pazzaglia; G Marchesini; P Pisi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

2.  [Chronic acquired hepatocerebral degeneration: the role of manganese and treatment by endovascular occlusion of a porto-systemic shunt].

Authors:  B Condat; A Dusoleil; M Bernardeau; A Roche; G Pelletier; C Buffet
Journal:  Gastroenterol Clin Biol       Date:  1999-02

3.  Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration.

Authors:  Hee K Park; Seung M Kim; Choong G Choi; Myoung C Lee; Sun J Chung
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

Review 4.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

5.  Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man.

Authors:  Karin Tuschl; Peter T Clayton; Sidney M Gospe; Shamshad Gulab; Shahnaz Ibrahim; Pratibha Singhi; Roosy Aulakh; Reinaldo T Ribeiro; Orlando G Barsottini; Maha S Zaki; Maria Luz Del Rosario; Sarah Dyack; Victoria Price; Andrea Rideout; Kevin Gordon; Ron A Wevers; W K Kling Chong; Philippa B Mills
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

6.  Increased manganese concentrations in pallidum of cirrhotic patients.

Authors:  G Pomier-Layrargues; L Spahr; R F Butterworth
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

7.  Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates.

Authors:  Tomás R Guilarte; Ming-Kai Chen; Jennifer L McGlothan; Tatyana Verina; Dean F Wong; Yun Zhou; Mohab Alexander; Charles A Rohde; Tore Syversen; Emmanuel Decamp; Amy Jo Koser; Stephanie Fritz; Heather Gonczi; David W Anderson; Jay S Schneider
Journal:  Exp Neurol       Date:  2006-08-22       Impact factor: 5.330

8.  Prominent cerebellar symptoms with unusual magnetic resonance imaging findings in acquired hepatocerebral degeneration.

Authors:  Sun Ah Park; Kyoung Heo
Journal:  Arch Neurol       Date:  2004-09

Review 9.  Parkinsonism in cirrhosis: pathogenesis and current therapeutic options.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2012-10-20       Impact factor: 3.584

10.  Cirrhosis presenting as Parkinsonism.

Authors:  Mohan L Noone; V G Pradeep Kumar; K Ummer; Laila Achambat; K A Salam
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

View more
  4 in total

Review 1.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

2.  Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease.

Authors:  A Pigoni; F Iuculano; C Saetti; L Airaghi; L Burdick; S Spreafico; M Curioni; R Lombardi; L Valenti; A L Fracanzani; S Fargion
Journal:  Metab Brain Dis       Date:  2017-09-16       Impact factor: 3.584

Review 3.  Management of Neurologic Manifestations in Patients with Liver Disease.

Authors:  José M Ferro; Pedro Viana; Patrícia Santos
Journal:  Curr Treat Options Neurol       Date:  2016-08       Impact factor: 3.598

4.  Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin.

Authors:  Ana L Sousa; Paula Salgado; José E Alves; Sara Silva; Sofia Ferreira; Marina Magalhães
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.